Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant rise » significant risk (Expand Search), significant risks (Expand Search), significant gap (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant rise » significant risk (Expand Search), significant risks (Expand Search), significant gap (Expand Search)
-
421
-
422
-
423
-
424
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
425
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
426
-
427
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
428
-
429
Amino acids interactions and binding energy describe that ABT-199 binds to ALK<sup>Mutant</sup>.
Published 2025Subjects: -
430
Activity of female and male <i>M. marinus</i> (left column) and <i>G. pulex</i> (right column).
Published 2025Subjects: -
431
-
432
-
433
-
434
-
435
-
436
-
437
-
438
ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side.
Published 2025Subjects: -
439
-
440
BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK<sup>mutants</sup>.
Published 2025Subjects: